• Citius Pharmaceuticals reported fiscal Q2 net loss applicable to common stockholders narrowed to USD 21.2 million, or USD 0.95 per share, from USD 10.9 million, or USD 1.27 per share, a year earlier.
• Revenue turned positive at USD 1.7 million from no revenue a year earlier, while gross margin held near 80%.
• Cash and cash equivalents totaled USD 4.6 million at March 31, 2026; Citius Pharma raised USD 5 million in a registered direct offering in April.
• At majority-owned Citius Oncology, LYMPHIR generated USD 5.6 million in net revenue in first half of fiscal 2026, with payer coverage near 100% of commercial lives and 83% of target accounts on formulary or in review.
• Subsequent to quarter end, Citius Oncology secured up to USD 36.5 million in combined debt and equity financing, with proceeds expected to fund operations through November 2026 and complete LYMPHIR field-force buildout by mid-summer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE61126) on May 15, 2026, and is solely responsible for the information contained therein.